Klotho gene and protein expression status in blood of Alzheimer’s patients treated with blood pressure or lipid controlling drugs

Document Type : Research Paper

Authors

1 Department of Physiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

2 Electrophysiological Research Center, Tehran University of Medical Sciences, Tehran, Iran and Registry Program of Cognitive Deficit and Alzheimer's Disease Information, Tehran Province, Tehran, Iran

3 Department of Physiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran and Department of Neuroscience, Faculty of Advanced Technologies in Medicine, Iran University of Medical Science, Tehran, Iran and Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran

4 Neurophysiology Research Center, Shahed University, Tehran, Iran

10.22070/jbcp.2023.18269.1174

Abstract

Background and Objective: Alzheimer’s disease (AD) as the most common neurodegenerative disorder. Klotho is an anti-aging protein with important roles in neurodegenerative disorders. This study was done to evaluate the expression of klotho gene and protein in the plasma of AD patients treated with blood pressure control drugs (inhibitors of angiotensin-converting enzyme (ACE)) or blood lipids control drug (simvastatin).
Materials and Methods: Target population was selected from people with AD who visited the neurology clinic of Firouzgar hospital. The tested groups included the control group, Alzheimer's group, Alzheimer's group treated with blood pressure control drugs, and Alzheimer's patients group treated with blood lipid control drug. Expression of klotho gene and protein in the plasma of studied groups was determined using real-time PCR and ELISA techniques and the individual's cognitive disorders were also evaluated using Mini-Mental State Exam (MMSE) and Clinical Dementia Rating (CDR) tests.
Results: The results obtained in this study showed that in addition to the significant difference in cognitive indices between the control groups and three groups of Alzheimer's patients, the level of klotho gene and protein expression was also lower in three groups of Alzheimer's patients compared to healthy group. However, there was no significant difference (p>0.05) between the Alzheimer's group and the two Alzheimer's groups treated with blood pressure or blood lipid control drugs.
Conclusion: Drugs controlling blood pressure or blood lipids in Alzheimer's patients possibly have no significant effect on the level of klotho protein. Obviously, more studies are needed in this field.
Materials and Methods: Target population was selected from people with AD who visited the neurology clinic of Firouzgar hospital. The tested groups included the control group, Alzheimer's group , Alzheimer's group treated with blood pressure control drugs, and Alzheimer's patients group treated with blood lipid control drug. Expression of klotho gene and protein in the plasma of studied groups was determined using real-time PCR and ELISA techniques and the individual's cognitive disorders were also evaluated using Mini-Mental State Exam (MMSE) and Clinical Dementia Rating (CDR) tests.
Results: The results obtained in this study showed that in addition to the significant difference in cognitive indices between the control groups and three groups of Alzheimer's patients, the level of klotho gene and protein expression was also lower in three groups of Alzheimer's patients compared to healthy group. However, there was no significant difference (p>0.05) between the Alzheimer's group and the two Alzheimer's groups treated with blood pressure or blood lipid control drugs.
Conclusion: Drugs controlling blood pressure or blood lipids in Alzheimer's patients possibly have no significant effect on the level of klotho protein. Obviously, more studies are needed in this field.

Keywords


  1. Knopman DS, Amieva H, Petersen RC, Chételat G, Holtzman DM, Hyman BT, et al. Alzheimer disease. Nature Reviews Disease Primers 2021;7(1):33.
  2. Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Chételat G, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimer's & Dementia 2014;10(6):844-52.
  3. Geldmacher DS, Whitehouse PJ. Evaluation of dementia. New England Journal of Medicine 1996;335(5):330-6.
  4. Dimities M, Xristina F, Theodora-Elesa K, Maria C. The Impact of Exercising in the Quality of Life of People with Dementia-Alzheimer's Disease. Advances in Experimental Medicine and Biology 2021;1339: 309-15.
  5. Iso-Markku P, Kujala UM, Knittle K, Polet J, Vuoksimaa E, Waller K. Physical activity as a protective factor for dementia and Alzheimer's disease: systematic review, meta-analysis and quality assessment of cohort and case-control studies. British Journal of Sports Medicine 2022;56(12):701-9.
  6. Li J, Guo Y, Yang K, Zhang G, Huang K, Zhou J, et al. Rehabilitation effects of game therapy in people living with dementia: A systematic review and meta-analysis: Three formats of game therapy for Alzheimer's patients. Worldviews on Evidence-Based Nursing 2023;20(4):361-76.
  7. Kuang X, Chen YS, Wang LF, Li YJ, Liu K, Zhang MX, et al. Klotho upregulation contributes to the neuroprotection of ligustilide in an Alzheimer's disease mouse model. Neurobiology of Aging 2014;35(1):169-78.
  8. Sedighi M, Baluchnejadmojarad T, Fallah S, Moradi N, Afshin-Majd S, Roghani M. The Association Between Circulating Klotho and Dipeptidyl Peptidase-4 Activity and Inflammatory Cytokines in Elderly Patients With Alzheimer Disease. Basic and Clinical Neuroscience 2020;11(3):349-57.
  9. Ananya FN, Ahammed MR, Lahori S, Parikh C, Lawrence JA, Sulachni F, et al. Neuroprotective Role of Klotho on Dementia. Cureus 2023;15(6):e40043.
  10. Abraham CR, Mullen PC, Tucker-Zhou T, Chen CD, Zeldich E. Klotho Is a Neuroprotective and Cognition-Enhancing Protein. Vitamins and Hormones 2016;101:215-38.
  11. Kim JH, Hwang KH, Park KS, Kong ID, Cha SK. Biological Role of Anti-aging Protein Klotho. Journal of Lifestyle Medicine 2015;5(1):1-6.
  12. Dalton GD, Xie J, An SW, Huang CL. New Insights into the Mechanism of Action of Soluble Klotho. Frontiers in Endocrinology 2017;8:323.
  1. Brombo G, Bonetti F, Ortolani B, Morieri ML, Bosi C, Passaro A, et al. Lower Plasma Klotho Concentrations Are Associated with Vascular Dementia but Not Late-Onset Alzheimer's Disease. Gerontology 2018;64(5):414-21.
  2. Torbus-Paluszczak M, Bartman W, Adamczyk-Sowa M. Klotho protein in neurodegenerative disorders. Neurological Sciences 2018;39(10):1677-82.
  3. Castner SA, Gupta S, Wang D, Moreno AJ, Park C, Chen C, et al. Longevity factor klotho enhances cognition in aged nonhuman primates. Nature Aging 2023;3(8):931-7.
  4. Sanz B, Arrieta H, Rezola-Pardo C, Fernández-Atutxa A, Garin-Balerdi J, Arizaga N, et al. Low serum klotho concentration is associated with worse cognition, psychological components of frailty, dependence, and falls in nursing home residents. Scientific Reports 2021;11(1):9098.
  5. Zhao Y, Zeng CY, Li XH, Yang TT, Kuang X, Du JR. Klotho overexpression improves amyloid-β clearance and cognition in the APP/PS1 mouse model of Alzheimer's disease. Aging Cell 2020;19(10):e13239.
  6. Yao Q, Jiang K, Lin F, Zhu T, Khan NH, Jiang E. Pathophysiological Association of Alzheimer's Disease and Hypertension: A Clinical Concern for Elderly Population. Clinical Interventions in Aging 2023;18:713-28.
  7. Rai S, Bhatia V, Bhatnagar S. Drug repurposing for hyperlipidemia associated disorders: An integrative network biology and machine learning approach. Computational Biology and Chemistry 2021;92:107505.
  8. Fan YC, Hsu JL, Tung HY, Chou CC, Bai CH. Increased dementia risk predominantly in diabetes mellitus rather than in hypertension or hyperlipidemia: a population-based cohort study. Alzheimer's Research & Therapy 2017;9(1):7.
  9. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 1975;12(3):189-98.
  10. Seyedian M, Falah M, Nourouzian M, Nejat S, Delavar A, Ghasemzadeh H. Validity of the Farsi version of mini-mental state examination.
  11. Behzad M, Zirak N, Madani GH, Baidoo L, Rezaei A, Karbasi S, et al. CSF-Targeted Proteomics Indicate Amyloid-Beta Ratios in Patients with Alzheimer's Dementia Spectrum. International Journal of Alzheimer's Disease 2023;2023:5336273.
  1. Bolós M, Perea JR, Avila J. Alzheimer's disease as an inflammatory disease. Biomolecular Concepts 2017;8(1):37-43.
  2. Gaitán JM, Asthana S, Carlsson CM, Engelman CD, Johnson SC, Sager MA, et al. Circulating Klotho Is Higher in Cerebrospinal Fluid than Serum and Elevated Among KLOTHO Heterozygotes in a Cohort with Risk for Alzheimer's Disease. Journal of Alzheimer's Disease 2022;90(4):1557-69.
  3. Bondi MW, Edmonds EC, Salmon DP. Alzheimer's Disease: Past, Present, and Future. Journal of the International Neuropsychological Society 2017;23(9-10):818-31.
  4. Suzuki K, Iwata A, Iwatsubo T. The past, present, and future of disease-modifying therapies for Alzheimer's disease. Proceedings of the Japan Academy,Ser. B, Physical and Biological Sciences 2017;93(10):757-71.
  5. Kocahan S, Doğan Z. Mechanisms of Alzheimer's Disease Pathogenesis and Prevention: The Brain, Neural Pathology, N-methyl-D-aspartate Receptors, Tau Protein and Other Risk Factors. Clinical Psychopharmacology and Neuroscience 2017;15(1):1-8.
  6. Cummings JL, Osse AML, Kinney JW. Alzheimer's Disease: Novel Targets and Investigational Drugs for Disease Modification. Drugs 2023, in press..
  7. Dave BP, Shah YB, Maheshwari KG, Mansuri KA, Prajapati BS, Postwala HI, et al. Pathophysiological Aspects and Therapeutic Armamentarium of Alzheimer's Disease: Recent Trends and Future Development. Cellular and Molecular Neurobiology 2023, in press.
  8. Singh YP, Kumar N, Chauhan BS, Garg P. Carbamate as a potential anti-Alzheimer's pharmacophore: A review. Drug Development Research 2023, in press.
  9. Fung TY, Iyaswamy A, Sreenivasmurthy SG, Krishnamoorthi S, Guan XJ, Zhu Z, et al. Klotho an Autophagy Stimulator as a Potential Therapeutic Target for Alzheimer's Disease: A Review. Biomedicines 2022;10(3).
  10. Fan L, Mao C, Hu X, Zhang S, Yang Z, Hu Z, et al. New Insights Into the Pathogenesis of Alzheimer's Disease. Frontiers in Neurology 2019;10:1312.
  11. Mytych J, Sołek P, Będzińska A, Rusinek K, Warzybok A, Tabęcka-Łonczyńska A, et al. Towards Age-Related Anti-Inflammatory Therapy: Klotho Suppresses Activation of ER and Golgi Stress Response in Senescent Monocytes. Cells 2020;9(2).
  1. Prud'homme GJ, Kurt M, Wang Q. Pathobiology of the Klotho Antiaging Protein and Therapeutic Considerations. Frontiers in Aging 2022;3:931331.
  2. Li D, Jing D, Liu Z, Chen Y, Huang F, Behnisch T. Enhanced Expression of Secreted α-Klotho in the Hippocampus Alters Nesting Behavior and Memory Formation in Mice. Frontiers in Cellular Neuroscience 2019;13:133.
  3. Lin Y, Kuro-o M, Sun Z. Genetic deficiency of anti-aging gene klotho exacerbates early nephropathy in STZ-induced diabetes in male mice. Endocrinology 2013;154(10):3855-63.
  4. Paroni G, Panza F, De Cosmo S, Greco A, Seripa D, Mazzoccoli G. Klotho at the Edge of Alzheimer's Disease and Senile Depression. Molecular Neurobiology 2019;56(3):1908-20.
  5. Semba RD, Moghekar AR, Hu J, Sun K, Turner R, Ferrucci L, et al. Klotho in the cerebrospinal fluid of adults with and without Alzheimer's disease. Neuroscience Letters 2014;558:37-40.
  6. Zhu Y, Prata L, Gerdes EOW, Netto JME, Pirtskhalava T, Giorgadze N, et al. Orally-active, clinically-translatable senolytics restore α-Klotho in mice and humans. EBioMedicine 2022;77:103912.
  7. Drew DA, Katz R, Kritchevsky S, Ix JH, Shlipak MG, Newman AB, et al. Soluble Klotho and Incident Hypertension. Clinical Journal of the American Society of Nephrology 2021;16(10):1502-11.